drugset / Trial / NCT03855826

Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.

NCT03855826

Phase 4 Unknown 756 enrolled Sichuan Baili Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

Efficacy and safety evaluation of amiodarone and Nifekalant hydrochloride(NIF) for the treatment of ventricular tachycardia and ventricular fibrillation.

Timeline

Start
2019-01-15
Primary completion
2020-01-30
Completion
2020-01-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amiodarone Small molecule Intravenous
Subject Nifekalant Small molecule 50 mg Intravenous